SERA — Sera Prognostics, Inc.

Sera Prognostics, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $10,000, down from $24,000 in Q4 2024.
• Full Year Revenue: $81,000, a slight increase from $77,000 in 2024.
• Operating Expenses: $9 million in Q4, down from $9.4 million in the prior year; total expenses for 2025 were $36.6 million, nearly flat compared to $36.7 million in 2024.
• Net Loss: $7.9 million for Q4, improved from $8.6 million in Q4 2024; total net loss for 2025 was $31.9 million, compared to $32.9 million in 2024.
• Cash Position: Ended 2025 with $95.8 million in cash and equivalents, providing runway through 2028.

2. Strategic Updates and Business Highlights:

• Leadership Expansion: Strengthened the team with new appointments including Lee Anderson (Chief Commercial Officer) and Dr. Tiffany Inglis (Chief Medical Officer).
• PRIME Study Publication: The pivotal PRIME study published in January 2026 showed significant reductions in preterm births (56% fewer before 32 weeks and 32% before 35 weeks).
• Commercial Strategy: Focus on expanding partner programs across 13 states, aiming for 5-7 active programs by the end of 2026. Plans to engage with 15-17 states and double payer engagements.
• International Expansion: Progressing towards CE marking approval for the PreTRM Global test in Europe, with submissions expected soon.

3. Forward Guidance and Outlook:

• Revenue Growth: Anticipated gradual revenue growth as partner programs mature and real-world evidence is generated.
• Investment Strategy: Focus on market access and commercial scale-up while maintaining financial discipline. Plans to reallocate funds from R&D to commercialization efforts.
• Long-Term Goals: Aiming to establish PreTRM as a standard of care in obstetric practices, with a strong emphasis on payer engagement and clinical adoption.

4. Bad News, Challenges, or Points of Concern:

• Revenue Fluctuations: Revenue remains modest and can vary significantly in early commercial stages, raising concerns about sustainability.
• High Operating Expenses: Despite a slight decrease, operating expenses remain substantial, and the net loss indicates ongoing financial challenges.
• Market Adoption Risks: The gradual nature of adoption poses risks, especially in a competitive landscape where other solutions may emerge.

5. Notable Q&A Insights:

• Payer Engagement: Discussion on how to convert payer discussions into contracts emphasized the importance of demonstrating both clinical and economic outcomes, particularly the reduction in NICU admissions.
• Feedback from Conferences: Positive engagement from the Society for Maternal-Fetal Medicine (SMFM) conference post-PRIME publication, indicating increased interest from providers and payers.
• Global Launch Balance: Questions about balancing investments between U.S. states and EU launch highlighted the need for strategic capital allocation as commercial opportunities develop.

Overall, Sera Prognostics is positioned for potential growth following the PRIME study publication, but faces challenges in revenue generation and market adoption that will require careful management and strategic execution moving forward.